ORAMED PHARMACEUTICALS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
ORAMED PHARMACEUTICALS INC. (ORMP) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $28.00 thousand for the 12-month period ending 2013-08-31, per its 10-K filed 2014-11-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2014-11-14
- ORAMED PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2013-08-31 was -$344.00.
- ORAMED PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2012-11-30 was $28.34K.
- ORAMED PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2013 was $28.00K, a 94.33% decline from fiscal 2012.
- ORAMED PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2012 was $494.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month as first filed |
|---|---|---|---|---|
| 2013-08-31 | -$344.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-14 | $28.00K 10-K · filed 2014-11-14 | $28.34K 10-K · filed 2013-11-27 | |
| 2013-05-31 | $28.34K 10-Q · filed 2013-07-17 | |||
| 2012-11-30 | $28.34K 10-Q · filed 2012-12-26 | |||
| 2012-08-31 | $494.00K 10-K · filed 2014-11-14 | $494.48K 10-K · filed 2012-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |